Status:
COMPLETED
Olanzapine in the Treatment of Patients With Anorexia Nervosa
Lead Sponsor:
Ottawa Hospital Research Institute
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Anorexia Nervosa
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
The purpose of the study is to evaluate the efficacy of an anti-psychotic medication, Olanzapine, in achieving desired weight gain in patients identified as having Anorexia Nervosa, either restricting...
Detailed Description
The purpose of the study is to evaluate the efficacy of an anti-psychotic medication, Olanzapine, in achieving desired weight gain in patients identified as having Anorexia Nervosa, either restricting...
Eligibility Criteria
Inclusion
- those who meet DSM IV criteria of Anorexia Nervosa- either restricting or binge/purge subtype
Exclusion
- patients who are actively self destructive and/or suicidal
- patients whose medical status is seriously compromised
- patients whose eating disorder is superimposed on a major psychiatric disorder such as schizophrenia, major affective disorders, dissociative disorder or an active substance abuse disorder.
Key Trial Info
Start Date :
September 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2006
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT00260962
Start Date
September 1 2000
End Date
September 1 2006
Last Update
January 30 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ottawa Hospital
Ottawa, Ontario, Canada, K1Y 4E9